198 results on '"Boyer, Michael J"'
Search Results
2. Testicular cancer : diagnosis and treatment
3. Mitochondrial Fission Mediates Endothelial Inflammation
4. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
5. Transduction Efficiency of Adenovirus Vectors in Endothelial Cells and Vascular Smooth Muscle Cells
6. Supplementary Figure 2 from Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
7. Supplementary Figure 1 from Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
8. Supplementary Figure Legends 1-2, Table Legend from Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
9. Data from Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
10. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
11. Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile–Induced Abdominal Aortic Aneurysm
12. The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with consolidation durvalumab.
13. IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).
14. The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
15. Effect of delayed consolidation durvalumab and timing of treatment on survival outcomes in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT).
16. A retrospective cohort analysis of return-to-work outcomes for cancer survivors using a digital coaching intervention.
17. Caveolin-1 Deletion Prevents Hypertensive Vascular Remodeling Induced by Angiotensin II
18. Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
19. Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
20. Multi-center phase 1 safety and efficacy study of nivolumab in renal transplant patients with metastatic malignancy.
21. Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma
22. Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF
23. ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling
24. Endothelial cell‐derived extracellular vesicles alter vascular smooth muscle cell phenotype through high‐mobility group box proteins
25. Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).
26. Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
27. Involvement of Senescence and Mitochondrial Fission in Endothelial Cell Pro-Inflammatory Phenotype Induced by Angiotensin II
28. Environmental Impact and Waste Management
29. Environmental Concerns
30. Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial
31. Pleural and pericardial effusions
32. Randomized Controlled Trial of the Role of Positron Emission Tomography in the Management of Stage I and II Non–Small-Cell Lung Cancer
33. Chapter 9 Measurement of Intracellular pH
34. Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
35. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
36. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
37. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer
38. A cytoskeletal anchor connects ischemic mitochondrial fission to myocardial senescence
39. New Chemotherapeutic Agents in the Treatment of Non-small Cell Lung Cancer*: The Australian Experience
40. Lysosomes, Lysosomal Enzymes, and Cancer
41. Ectopic corticotropin syndrome and small-cell carcinoma of the lung: clinical features, outcome, and complications
42. Vascular ADAM17 is required for angiotensin II/β-aminopropionitrile-induced abdominal aortic aneurysm
43. Transduction Efficiency of Adenovirus Vectors in Endothelial Cells and Vascular Smooth Muscle Cells.
44. Novel role for cardiac myocyte-derived β-2 microglobulin in mediating cardiac fibrosis
45. Abstract P243: Vascular Drp1 Mediates Angiotensin II-Induced Cardiovascular Hypertrophy via Global as Well as Selective de novo Protein Synthesis.
46. Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing
47. Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
48. Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes
49. Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
50. Association between efficacy of immunotherapy and rate of cancer progression at the time of initiation of immunotherapy: An analysis in metastatic non-small cell lung cancer (NSCLC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.